GP2 Study Overview
The Global Parkinson’s Genetics Program (GP2), supported by the Aligning Science Across Parkinson’s (ASAP) initiative, is an international collaborative effort aimed at making transformational progress in Parkinson’s disease (PD) genetics.
The aim of GP2 is not simply to improve our understanding of the role that genetics plays in PD across world populations, but to also make that understanding actionable. The path to achieving this vision involves the formation of a cohesive group of collaborators; data collection, production and harmonization at scale; training of analysts around the world; and the development of a portal that democratizes data and analytical resources.
Bringing together collaborators from Africa, Asia, Central America, the Caribbean, Europe, the Middle East, North America, Oceania, and South America, GP2 will integrate and generate critical clinical and genetic data. Using these data, GP2 will accelerate the identification of novel risk loci and monogenic causes of disease, identify genetic modifiers of disease phenotype and monogenic penetrance, fine map risk loci, and understand population differences in PD genetics.
If you have any questions, please contact GP2.
GP2 Goals and Objectives
To dramatically expand the understanding of the genetic basis of PD and to make that knowledge globally relevant.
Complex Disease - dramatic expansion of known genetic risk
Goal - Whole genome genotyping of >150,000 individuals
- Doubling known risk loci
- Improved PRS for prediction and modeling
- Mutation carriers identified
- Genetic basis of PD onset and progression
- Genetic modifiers of LRRK2 and GBA
- Samples, tissues, cells available for follow-up analyses
Monogenic Disease - enabling, accelerating, improving mutation discovery
Goal - Whole genome sequencing of >10,000 individuals
- Rapid identification of new causal genes
- Validation resource for new genes/mutations
- Long-read sequencing resource
- Exploration of SV and repeats in disease causation
- Samples, tissues, cells available with known genetic architecture
Global Disease - making understanding of PD genetics globally relevant
Goal - Ancestral diversity in all genetic analyses
- Black Americans, Africa, South and Central America, East Asia, Central Asia
- Mapping heterogeneity
- Accelerated fine mapping to reveal effector gene and mechanism
- Identification of populations enriched for genetic factors
- Diverse patient samples, tissues, cells with known genetic architecture
- Democratization of Data
- Collaboration and Cooperation
- Safe, Responsible Data Sharing
- Diversity in Research and Researchers
- Accessible, transparent and reproducible workflows
- Foundational, Actionable Resource Production
Study Specific Data Contribution
As of December 2021, genotyped data of over 4,908 participants will be accessible through your AMP PD DUA. The GP2 data streams, data releases, and the data available to you will continue to evolve and expand with time.
GP2 Announces First Data Release: https://gp2.org/news/gp2-announces-first-data-release/
GP2 Cohort Dashboard: https://gp2.org/cohort-dashboard/
Inclusion and Exclusion Criteria
Selection criteria: Sample availability from additional affected family members, genetic pre-screening, consanguinity, age at onset, ethnicity, and reviewer’s opinion
Updates to GP2 Cohort Data Usage Terms
AMP PD and GP2 use the same data usage agreement (DUA), but have differences in IP and publication policies. Per the AMP PD DUA, the GP2 Access Compliance Team "...may notify users of additional GP2-specific data usage requirements from time to time." To ensure that the user is up to date on all GP2 specific changes to these policies, please check the links below regularly for further information.
GP2 Intellectual Property Policy : https://gp2.org/resources/intellectual-property-policy/
GP2 Publication Policy: https://gp2.org/resources/publicationpolicy/